- Zacks•19 days ago
Merrimack's (MACK) seribantumab (MM-121) gets Fast Track designation for the treatment of non-small cell lung cancer in the U.S.
Merrimack Pharmaceuticals, Inc.NasdaqGM
After hours: 5.630.00 (0.00%) as of 5:18 PM EDT
|Bid||5.48 x 100|
|Ask||5.78 x 100|
|52wk Range||5.02 - 11.18|
|Day's Range||5.51 - 5.69|
|Avg Vol (3m)||1,730,758|
As of 4:00 PM EDT. Market closed.